Avoiding the rebound, therefore, lies in the GLP-1 patients ability to embrace healthier eating while on the drugs and then sustaining these new habits when they finish taking them, explains UK dietician and nutritionist, Dr Sarah Schenker
2014 follow-up study was retracted in 2025, which means the foundational evidence base has significant integrity concerns that should be weighed carefully
Retatrutide remains investigational and has not been approved for general clinical use
This is particularly important given that changes in weight and metabolism, which can occur with long-term semaglutide use, may affect thyroid hormone requirements
Blood tests from studies of exenatide, another GLP-1 medication, showed that the drug reduced alcohol consumption compared to placebo